Vanguard Group Inc. Has $15.66 Million Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Vanguard Group Inc. decreased its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 1.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,000,022 shares of the company’s stock after selling 35,341 shares during the period. Vanguard Group Inc.’s holdings in Y-mAbs Therapeutics were worth $15,660,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. KLP Kapitalforvaltning AS bought a new stake in Y-mAbs Therapeutics in the fourth quarter valued at approximately $46,000. SG Americas Securities LLC raised its stake in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after purchasing an additional 4,163 shares during the period. Principal Financial Group Inc. lifted its stake in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares in the last quarter. AlphaQuest LLC boosted its holdings in Y-mAbs Therapeutics by 6,911.6% during the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock worth $212,000 after purchasing an additional 26,748 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 22.50% of the stock is owned by corporate insiders.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $4.69 on Friday. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.86 and a 1 year high of $17.78. The stock has a market cap of $212.07 million, a price-to-earnings ratio of -8.69 and a beta of 0.71. The company has a 50 day simple moving average of $5.08 and a 200 day simple moving average of $8.58.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same period in the previous year, the business posted ($0.02) earnings per share. On average, equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

YMAB has been the subject of several analyst reports. Wedbush reissued an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America lowered their target price on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, Truist Financial reduced their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.30.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.